U.S.-U.K. Negotiations Could Lead To Higher Drug Spending In Britain

The U.K.’s National Institute for Health and Care Excellence (NICE) is considering raising the cost-effectiveness threshold for the first time in 26 years. This threshold is crucial as it represents the maximum amount that the healthcare system is willing to pay for an additional unit of health benefit, typically measured in quality-adjusted life years (QALYs). It serves as a signal of what the government is willing to pay for healthcare interventions.

Recently, there has been a significant decline in foreign direct investment in the British life sciences sector, falling by 58% from £1.9 billion in 2021 to £795 million in 2023. To address this issue and potentially appease President Trump, the British government is contemplating raising the cost-effectiveness threshold used as a benchmark to determine value for money for the National Health Service (NHS).

NICE evaluates medicines and medical technologies based on clinical- and cost-effectiveness, as well as the overall cost to the NHS. Currently, NICE considers medicines costing between £20,000 and £30,000 per additional QALY gained to provide good value for money for the NHS. However, this range has been in place since 1999, and there are discussions about potentially increasing it to £25,000-£37,500 per QALY.

The Association of the British Pharmaceutical Industry (ABPI) has advocated for a larger increase in the threshold to £40,000-£50,000, indexed to inflation thereafter. This change would require additional funding to support it. Advocates for a threshold increase emphasize the need for better uptake of new medicines in Britain, ensuring rapid and equitable access across the nation.

However, raising the threshold without a corresponding increase in pharmaceutical budgets could lead to delays in treatment for patients. Health Secretary Wes Streeting is proposing a “top-up” fund for increased pharmaceutical spending, rather than relying on existing NHS budgets. The decision on the cost-effectiveness threshold will have far-reaching implications for the pharmaceutical industry and patient access to innovative treatments.

In conclusion, the decision on revising the cost-effectiveness threshold is a complex one that requires balancing societal health, fairness, and innovation. It is essential for the threshold to evolve with evidence and policy priorities to ensure that patients receive timely and appropriate access to healthcare interventions. The outcome of these deliberations will not only impact the U.K. healthcare system but will also be influenced by external factors, including global pharmaceutical policies and regulations.